ELAN
Elanco Animal Health Incorporated
ELAN lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to recover and profitability to improve, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ELAN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Weak |
ELAN's revenue and cash flow are currently healthy, but its profitability and balance sheet are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ELAN PE Valuation
ELAN has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ELAN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
ELAN has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ELAN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.24 | — |
| Q3 2026 | -$0.29 | -514% |
| Q2 2026 | -$0.40 | -146% |
| Q1 2026 | -$0.49 | -165% |
| Q4 2025 | -$0.47 | -169% |
| Q3 2025 | $0.07 | -83% |
| Q2 2025 | $0.87 | +$3.42 |
| Q1 2025 | $0.75 | +$3.40 |
| Q4 2024 | $0.68 | +$3.18 |
ELAN has swung to a loss: it lost $0.29 per share over the past year, after a profit the year before.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over ELAN on earnings, with more consistent year-over-year improvement.
ELAN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.3B | +11% |
| Q2 2026 | $1.4B | +10% |
| Q1 2026 | $1.4B | +15% |
| Q4 2025 | $1.1B | +12% |
| Q3 2025 | $1.1B | +10% |
| Q2 2025 | $1.2B | +4.8% |
| Q1 2025 | $1.2B | -1% |
| Q4 2024 | $1B | -1.4% |
ELAN's revenue has grown year over year for six quarters in a row: $1.3B last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.9% | +6.3 points |
| Q2 2026 | 4.1% | +2.1 points |
| Q1 2026 | 6.3% | +1.3 points |
| Q4 2025 | -23% | -18 points |
| Q3 2025 | -4.4% | -59 points |
| Q2 2025 | 2% | +4.7 points |
| Q1 2025 | 5% | +4 points |
| Q4 2024 | -5% | +7.3 points |
ELAN has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ELAN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ELAN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $156M | +23% |
| Q2 2026 | $244M | +36% |
| Q1 2026 | -$38M | +$31M |
| Q4 2025 | $46M | -65% |
| Q3 2025 | $127M | +5.8% |
| Q2 2025 | $180M | +8.4% |
| Q1 2025 | -$69M | -$47M |
| Q3 2024 | $120M | -39% |
ELAN generated $408M in free cash flow over the past year, up 11% from the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ELAN on cash flow, with more consistent year-over-year improvement.
ELAN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +600K shares |
| 1 year | +2% | +9.7M shares |
| 3 years | +2.8% | +13.8M shares |
| 5 years | +3.9% | +19.2M shares |
| Available history | +37% | +136M shares |
ELAN has 507M diluted shares, up 2% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ELAN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ELAN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.4x | High |
| Q2 2026 | 6.4x | High |
| Q1 2026 | 7.2x | High |
| Q4 2025 | 7.6x | High |
| Q3 2025 | 5.4x | High |
| Q2 2025 | 2.9x | Moderate |
| Q1 2025 | 3.3x | Elevated |
| Q4 2024 | 3.4x | Elevated |
ELAN's net debt is about 5.4 years of its operating earnings (EBITDA), about the same as a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ELAN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.4 | Neutral |
| Stochastic | 59.7 | Neutral |
ELAN's weekly RSI is 61 (neutral) and its Stochastic is 60 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ELAN PE vs Healthcare Sector
| Metric | ELAN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ELAN has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ELAN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.6 | 12% above |
| 20 week MA | $24.0 | 11% above |
| 50 week MA | $23.7 | 12% above |
| 100 week MA | $19.2 | 38% above |
| 200 week MA | $16.0 | 65% above |
ELAN has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ELAN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.3 | $30.5 | +4.1% |
| 2021 | $30.5 | $28.9 | -5.4% |
| 2022 | $28.9 | $11.7 | -59% |
| 2023 | $11.7 | $14.9 | +27% |
| 2024 | $14.9 | $12.1 | -19% |
| 2025 | $12.1 | $22.6 | +87% |
| 2026 YTD | $22.6 | $26.5 | +17% |
ELAN has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.